Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program-Reference-Cited by-同舟云学术

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

Published:2013-06-24 Issue:11 Volume:60 Page:1860-1867
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Wood Andrew C.¹,Maris John M.¹,Gorlick Richard²,Kolb E. Anders³,Keir Stephen T.⁴,Reynolds C. Patrick⁵,Kang Min H.⁵,Wu Jianrong⁶,Kurmasheva Raushan T.⁷,Whiteman Kathleen⁸,Houghton Peter J.⁷,Smith Malcolm A.⁹

Affiliation:

1. Hematology-Oncology Division of Oncology, Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute; Philadelphia Pennsylvania

2. The Children's Hospital at Montefiore; Bronx New York

3. A.I. duPont Hospital for Children; Wilmington Delaware

4. Duke University Medical Center; Durham North Carolina

5. Texas Tech University Health Sciences Center; Lubbock Texas

6. St. Jude Children's Research Hospital; Memphis Tennessee

7. Nationwide Children's Hospital; Columbus Ohio

8. ImmunoGen, Inc.; Waltham Maryland

9. Cancer Therapy Evaluation Program, NCI; Bethesda Maryland

Funder

National Cancer Institute

Robert Lutz of ImmunoGen, Inc.

Publisher